Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: mistake (35), fault (22), slip (31)

Selinexor Bortezomib Dexamethasone

Description: Chemotherapy Protocol Multiple Myeloma Selinexor with Bortezomib and Dexamethasone Regimen • SELINEXOR (PO) – BORTEZOMIB (SC) – DEXAMETHASONE (PO) Indication Selinexor plus bortezomib and
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Selinexor-Bortezomib-Dexamethasone-Ver1.pdf

Epcoritamab -Cycle 2 (Onwards)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB – Cycle 2 Onwards - (28 day) Regimen • Lymphoma-Epcoritamab – Cycle 2 Onwards - (28 day) Indication • Treatment of adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-2-Onwards-Ver1.pdf

Epcoritamab -Cycle 1 (Priming)

Description: Chemotherapy Protocol LYMPHOMA EPCORITAMAB -Cycle 1 - (28 Day -Priming) Regimen • Lymphoma-Epcoritamab – Cycle 1- (28 day -Priming) Indication • Treatment of adult
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Epcoritamab-Cycle-1-Priming-Ver1.pdf

Tarlatamab (EAMS)

Description: Chemotherapy Protocol LUNG CANCER – SMALL CELL (SCLC) Tarlatamab (EAMS) Regimen • SCLC – Tarlatamab (EAMS) Indication • Tarlatamab is indicated as monotherapy for the
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Tarlatamab-EAMS-Ver-1.0.pdf

AtezolizumabSC Bevacizumab Carboplatin Paclitaxel

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ATEZOLIZUMAB-SC-BEVACIZUMAB-CARBOPLATIN (AUC6)-PACLITAXEL Regimen • Lung-Atezolizumab-SC-Bevacizumab-Carboplatin (AUC6
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/AtezolizumabSC-Bevacizumab-Carboplatin-Paclitaxel-Ver1.0.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

Atezolizumab SC-Carboplatin(AUC5)-Etoposide (IV/PO)

Description: Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-SC-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen • Lung - AtezolizumabSC-Carboplatin (AUC5)-Etoposide(IV
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-SC-CarboplatinAUC5-Etoposide-IVPO.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description: Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH) Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel-PertuzumabTrastuzumab (EC-PPH) Indication • Neo
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

Carboplatin-Docetaxel-Pertuzumab-Trastuzumab_IV-SC

Description: Chemotherapy Protocol BREAST CANCER CARBOPLATIN (AUC6)-DOCETAXEL- PERTUZUMABTRASTUZUMAB (IV/SC) Regimen • Breast Cancer – Carboplatin (AUC6)-Docetaxel-Pertuzumab-Trastuzumab (IV/SC) Indication
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Carboplatin-Docetaxel-Pertuzumab-Trastuzumab-IV-SC.pdf

Atezolizumab (1875mg 21-days) SC

Description: Chemotherapy Protocol UROTHELIAL CANCER Atezolizumab SC (1875mg – 21 days) Regimen • Urothelial cancer – Atezolizumab monotherapy (1st or 2nd line) Indications • First line
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Atezolizumab-SC-1875mg-21-days.pdf

261 to 270 of 630

Previous … 25 26 27 28 29 … Next